Beyond atrophy: Redox mechanisms of muscle dysfunction in chronic inflammatory disease

Journal of Physiology

Volumn 589, Issue 9, 2011, Pages 2171-2179

  Reid, Michael B ^a   Moylan, Jennifer S ^a  

^a UNIVERSITY OF KENTUCKY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCYSTEINE; NITRIC OXIDE; REACTIVE OXYGEN METABOLITE; TROLOX C; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR RECEPTOR 1;

ANTIOXIDANT ACTIVITY; CHRONIC INFLAMMATION; CONFERENCE PAPER; CONTRACTILE DYSFUNCTION; HUMAN; MOTOR DYSFUNCTION; MUSCLE ATROPHY; MUSCLE DEVELOPMENT; MUSCLE FIBRIL; MUSCLE FORCE; MUSCLE WEAKNESS; NONHUMAN; OXIDATION REDUCTION REACTION; OXIDATIVE STRESS; PRIORITY JOURNAL; PROGNOSIS; PROTEIN FUNCTION; PROTEIN PROCESSING; RISK FACTOR; SIGNAL TRANSDUCTION;

ANIMALS; CHRONIC DISEASE; HUMANS; INFLAMMATION; INFLAMMATION MEDIATORS; MUSCLE CONTRACTION; MUSCLE STRENGTH; MUSCLE WEAKNESS; MUSCLE, SKELETAL; MUSCULAR ATROPHY; OXIDATION-REDUCTION; OXIDATIVE STRESS; REACTIVE OXYGEN SPECIES; RECEPTORS, TUMOR NECROSIS FACTOR, TYPE I; SIGNAL TRANSDUCTION; TUMOR NECROSIS FACTOR-ALPHA;

EID: 79955425383     PISSN: 00223751     EISSN: 14697793     Source Type: Journal    
DOI: 10.1113/jphysiol.2010.203356     Document Type: Conference Paper

References (70)

1. Adam-Klages S, Schwandner R, Adam D, Kreder D, Bernardo K & Kronke M (1997). Distinct adapter proteins mediate acid versus neutral sphingomyelinase activation through the p55 receptor for tumor necrosis factor. J Leukoc Biol 63, 678-682.
2. Alloatti G, Penna C, Mariano F & Camussi G (2000). Role of NO and PAF in the impairment of skeletal muscle contractility induced by TNF-α Am J Physiol Regul Integr Comp Physiol 279, R2156-R2163.
3. Andrade FH, Reid MB, Allen DG & Westerblad H (1998a). Effect of hydrogen peroxide and dithiothreitol on contractile function of single skeletal muscle fibres from the mouse. J Physiol 509, 565-575.
4. Andrade FH, Reid MB, Allen DG & Westerblad H (1998b). Effect of nitric oxide on single skeletal muscle fibres from the mouse. JPhysiol 509, 577-586.
5. Andrade FH, Reid MB & Westerblad H (2001). Contractile response to low peroxide concentrations: myofibrillar calcium sensitivity as a likely target for redox modulation of skeletal muscle function. FASEB J 15, 309-311.
6. Burke M, Reisler F & Harrington WF (1976). Effect of bridging the two essential thiols of myosin on its spectral and actin-binding properties. Biochemistry 15, 1923-1927.
7. Carmo MM, Barbara C, Ferreira T, Branco J, Ferreira S & Rendas AB (2001). Diaphragmatic function in patients with chronic left ventricular failure. Pathophysiology 8, 55-60.
8. Chen SE, Gerken E, Zhang Y, Zhan M, Mohan RK, Li AS, Reid MB & Li YP (2005). Role of TNF-α signaling in regeneration of cardiotoxin-injured muscle. Am J Physiol Cell Physiol 289, C1179-C1187.
9. Chua TP, Anker SD, Harrington D & Coats AJ (1995). Inspiratory muscle strength is a determinant of maximum oxygen consumption in chronic heart failure. Br Heart J 74, 381-385.
10. Cicoira M, Bolger AP, Doehner W, Rauchhaus M, Davos C, Sharma R, Al-Nasser FO, Coats AJ & Anker SD (2001). High tumour necrosis factor-α levels are associated with exercise intolerance and neurohormonal activation in chronic heart failure patients. Cytokine 15, 80-86.
11. Coirault C, Guellich A, Bargry T, Samuel JL, Riou B & Lecarpentier Y (2007). Oxidative stress of myosin contributes to skeletal muscle dysfunction in rats with chronic heart failure. Am J Physiol Heart Circ Physiol 292, H1009-H1017.
12. Collins RA & Grounds MD (2001). The role of tumor necrosis factor-alpha (TNF-α) in skeletal muscle regeneration. Studies in TNF-α(-/-) and TNF-α(-/-)/LT-α(-/-) mice. J Histochem Cytochem 49, 989-1001.
13. Dalla Libera L, Ravara B, Gobbo V, Danieli Betto D, Germinario E, Angelini A & Vescovo G (2005). Skeletal muscle myofibrillar protein oxidation in heart failure and the protective effect of Carvedilol. J Mol Cell Cardiol 38, 803-807.
14. de Angelis L, Zhao J, Andreucci JJ, Olson EN, Cossu G & McDermott JC (2005). Regulation of vertebrate myotome development by the p38 MAP kinase-MEF2 signaling pathway. Dev Biol 283, 171-179.
15. De Bleecker JL, Meire VI, Declercq W & Van Aken EH (1999). Immunolocalization of tumor necrosis factor-alpha and its receptors in inflammatory myopathies. Neuromuscul Disord 9, 239-246.
16. Doehner W, Bunck AC, Rauchhaus M, von Haehling S, Brunkhorst FM, Cicoira M, Tschope C, Ponikowski P, Claus RA & Anker SD (2007). Secretory sphingomyelinase is upregulated in chronic heart failure: a second messenger system of immune activation relates to body composition, muscular functional capacity, and peripheral blood flow. Eur Heart J 28, 821-828.
17. Evans SA, Watson L, Hawkins M, Cowley AJ, Johnston ID & Kinnear WJ (1995). Respiratory muscle strength in chronic heart failure. Thorax 50, 625-628.
18. Ferreira LF, Smith JD, Moylan JS & Reid MB (2010). Sphingomyelinase and ceramide increase reactive species and depress maximal skeletal muscle force in vitro. FASEB J 24, 801.16.
19. Fox TE, Houck KL, O'Neill SM, Nagarajan M, Stover TC, Pomianowski PT, Unal O, Yun JK, Naides SJ & Kester M (2007). Ceramide recruits and activates protein kinase C ζ (PKCζ) within structured membrane microdomains. J Biol Chem 282, 12450-12457.
20. Gan WQ, Man SFP, Senthilselvan A & Sin DD (2004). Association between chronic obstructive pulmonary disease and systemic inflammation: a systematic review and a meta-analysis. Thorax 59, 574-580.
21. 2 modulates cytosolic oxidant activity and contractile function in murine skeletal muscle cells. J Appl Physiol 100, 399-405.
22. Goodpaster BH, Park SW, Harris TB, Kritchevsky SB, Nevitt M, Schwartz AV, Simonsick EM, Tylavsky FA, Visser M & Newman AB (2006). The loss of skeletal muscle strength, mass, and quality in older adults: the health, aging and body composition study. J Gerontol A Biol Sci Med Sci 61, 1059-1064.
23. Hairi NN, Cumming RG, Naganathan V, Handelsman DJ, Le Couteur DG, Creasey H, Waite LM, Seibel MJ & Sambrook PN (2010). Loss of muscle strength, mass (sarcopenia), and quality (specific force) and its relationship with functional limitation and physical disability: the Concord Health and Ageing in Men Project. J Am Geriatr Soc 58, 2055-2062.
24. Hammond MD, Bauer KA, Sharp JT & Rocha RD (1990). Respiratory muscle strength in congestive heart failure. Chest 98, 1091-1094.
25. Hardin BJ, Campbell KS, Smith JD, Arbogast S, Smith J, Moylan JS & Reid MB (2008). TNF-α acts via TNFR1 and muscle-derived oxidants to depress myofibrillar force in murine skeletal muscle. J Appl Physiol 104, 694-699.
26. Harrington D, Anker SD, Chua TP, Webb-Peploe KM, Ponikowski PP, Poole-Wilson PA & Coats AJ (1997). Skeletal muscle function and its relation to exercise tolerance in chronic heart failure. J Am Coll Cardiol 30, 1758-1764.
27. Helliwell PS & Jackson S (1994). Relationship between weakness and muscle wasting in rheumatoid arthritis. Ann Rheum Dis 53, 726-728.
28. Howell S, Maarek JM, Fournier M, Sullivan K, Zhan WZ & Sieck GC (1995). Congestive heart failure: differential adaptation of the diaphragm and latissimus dorsi. J Appl Physiol 79, 389-397.
29. Levine S, Nguyen T, Kaiser LR, Rubinstein NA, Maislin G, Gregory C, Rome LC, Dudley GA, Sieck GC & Shrager JB (2003). Human diaphragm remodeling associated with chronic obstructive pulmonary disease: clinical implications. Am J Respir Crit Care Med 168, 706-713.
30. Li X, Moody MR, Engel D, Walker S, Clubb FJ Jr, Sivasubramanian N, Mann DL & Reid MB (2000). Cardiac-specific overexpression of tumor necrosis factor-α causes oxidative stress and contractile dysfunction in mouse diaphragm. Circulation 102, 1690-1696.
31. Lin LL, Wartmann M, Lin AY, Knopf JL, Seth A & Davis RJ (1993). cPLA2 is phosphorylated and activated by MAP kinase. Cell 72, 269-278.
32. Linke A, Adams V, Schulze PC, Erbs S, Gielen S, Fiehn E, Mobius-Winkler S, Schubert A, Schuler G & Hambrecht R (2005). Antioxidative effects of exercise training in patients with chronic heart failure: increase in radical scavenger enzyme activity in skeletal muscle. Circulation 111, 1763-1770.
33. Liu DF, Wang D & Stracher A (1990). The accessibility of the thiol groups on G- and F-actin of rabbit muscle. Biochem J 266, 453-459.
34. Liu H, Chen SE, Jin B, Carson JA, Niu A, Durham W, Lai JY & Li YP (2010). TIMP3: a physiological regulator of adult myogenesis. J Cell Sci 123, 2914-2921.
35. Lluis F, Ballestar E, Suelves M, Esteller M & Munoz-Canoves P (2005). E47 phosphorylation by p38 MAPK promotes MyoD/E47 association and muscle-specific gene transcription. EMBO J 24, 974-984.
36. McParland C, Krishnan B, Wang Y & Callagher CG (1992). Inspiratory muscle weakness and dyspnea in chronic heart failure. Am Rev Resp Dis 146, 467-472.
37. Mancini DM, Henson D, LaManca J & Levine S (1994). Evidence of reduced respiratory muscle endurance in patients with heart failure. J Am Coll Cardiol 24, 972-981.
38. Meyer FJ, Borst MM, Zugck C, Kirschke A, Schellberg D, Kübler W & Haass M (2001). Respiratory muscle dysfunction in congestive heart failure: clinical correlation and prognostic significance. Circulation 103, 2153-2158.
39. Ottenheijm CAC, Heunks LMA, Sieck GC, Zhan WZ, Jansen SM, Degens H, de Boo T & Dekhuijzen PNR (2005). Diaphragm dysfunction in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 172, 200-205.
40. Puri PL, Wu Z, Zhang P, Wood LD, Bhakta KS, Han J, Feramisco JR, Karin M & Wang JY (2000). Induction of terminal differentiation by constitutive activation of p38 MAP kinase in human rhabdomyosarcoma cells. Genes Dev 14, 574-584.
41. Putkey JA, Dotson DG & Mouawad P (1993). Formation of inter- and intramolecular bonds can activate cardiac troponin C. J Biol Chem 268, 6827-6830.
42. Reid MB, Lännergren J & Westerblad H (2002). Respiratory and limb muscle weakness induced by tumor necrosis factor-α: involvement of muscle myofilaments. Am J Respir Crit Care Med 166, 479-484.
43. Reid MB & Li YP (2001). Tumor necrosis factor-α and muscle wasting: a cellular perspective. Respir Res 2, 269-272.
44. 2 superfamily and its group numbering system. Biochim Biophys Acta 1761, 1246-1259.
45. Schonwasser DC, Marais RM, Marshall CJ & Parker PJ (1998). Activation of the mitogen-activated protein kinase/extracellular signal-regulated kinase pathway by conventional, novel, and atypical protein kinase C isotypes. Mol Cell Biol 18, 790-798.
46. Stassijns G, Gayan-Ramirez G, De Leyn P, de Bock V, Dom R, Lysens R & Decramer M (1999). Effects of dilated cardiomyopathy on the diaphragm in the Syrian hamster. Eur Respir J 13, 391-397.
47. Stenstrom CH & Minor MA (2003). Evidence for the benefit of aerobic and strengthening exercise in rheumatoid arthritis. Arthritis Rheum 49, 428-434.
48. Suematsu N, Tsutsui H, Wen J, Kang D, Ikeuchi M, Ide T, Hayashidani S, Shiomi T, Kubota T, Hamasaki N & Takeshita A (2003). Oxidative stress mediates tumor necrosis factor-α-induced mitochondrial DNA damage and dysfunction in cardiac myocytes. Circulation 107, 1418-1423.
49. Supinski G, DiMarco A & Dibner-Dunlap M (1994). Alterations in diaphragm strength and fatiguability in congestive heart failure. J Appl Physiol 76, 2707-2713.
50. Supinski GS & Callahan LA (2005). Diaphragmatic free radical generation increases in an animal model of heart failure. J Appl Physiol 99, 1078-1084.
51. Szentesi P, Bekedam MA, van Beek-Harmsen BJ, van der Laarse WJ, Zaremba R, Boonstra A, Visser FC & Stienen GJM (2005). Depression of force production and ATPase activity in different types of human skeletal muscle fibers from patients with chronic heart failure. J Appl Physiol 99, 2189-2195.
52. Tcherkasowa AE, Adam-Klages S, Kruse ML, Wiegmann K, Mathieu S, Kolanus W, Krönke M & Adam D (2002). Interaction with factor associated with neutral sphingomyelinase activation, a WD motif-containing protein, identifies receptor for activated C-kinase 1 as a novel component of the signaling pathways of the p55 TNF receptor. J Immunol 169, 5161-5170.
53. Tikunov BA, Mancini D & Levine S (1996). Changes in myofibrillar protein composition of human diaphragm elicted by congestive heart failure. J Mol Cell Cardiol 28, 2537-2541.
54. Tisdale MJ (2008). Catabolic mediators of cancer cachexia. Curr Opin Support Palliat Care 2, 256-261.
55. Toth MJ, Ades PA, Tischler MD, Tracy RP & LeWinter MM (2006). Immune activation is associated with reduced skeletal muscle mass and physical function in chronic heart failure. Int J Cardiol 109, 179-187.
56. van Hees HWH, van der Heijden HFM, Ottenheijm CAC, Heunks LMA, Pigmans CJC, Verheugt FWA, Brouwer RMHJ & Dekhuijzen PNR (2007). Diaphragm single-fiber weakness and loss of myosin in congestive heart failure rats. Am J Physiol Heart Circ Physiol 293, H819-H828.
57. van Norren K, Kegler D, Argilés JM, Luiking Y, Gorselink M, Laviano A, Arts K, Faber J, Jansen H, van der Beek EM & van Helvoort A (2009). Dietary supplementation with a specific combination of high protein, leucine, and fish oil improves muscle function and daily activity in tumour-bearing cachectic mice. Br J Cancer 100, 713-722.
58. Vescovo G, Ravara B & Dalla Libera L (2008). Skeletal muscle myofibrillar protein oxidation and exercise capacity in heart failure. Basic Res Cardiol 103, 285-290.
59. Warren GL, Hulderman T, Jensen N, McKinstry M, Mishra M, Luster MI & Simeonova PP (2002). Physiological role of tumor necrosis factor α in traumatic muscle injury. FASEB J 16, 1630-1632.
60. Weber MA, Krakowski-Roosen H, Schroder L, Kinscherf R, Krix M, Kopp-Schneider A, Essig M, Bachert P, Kauczor HU & Hildebrandt W (2009). Morphology, metabolism, microcirculation, and strength of skeletal muscles in cancer-related cachexia. Acta Oncol 48, 116-124.
61. Weiner P, Waizman J, Magadle R, Berar-Yanay N & Pelled B (1999). The effect of specific inspiratory muscle training on the sensation of dyspnea and exercise tolerance in patients with congestive heart failure. Clin Cardiol 22, 727-732.
62. Wiegmann K, Schutze S, Machleidt T, Witte D & Kronke M (1994). Functional dichotomy of neutral and acidic sphingomyelinases in tumor necrosis factor signaling. Cell 78, 1005-1015.
63. Wilcox P, Milliken C & Bressler B (1996). High-dose tumor necrosis factor alpha produces an impairment of hamster diaphragm contractility. Attenuation with a prostaglandin inhibitor. Am J Respir Crit Care Med 153, 1611-1615.
64. Wilcox PG, Wakai Y, Walley KR, Cooper DJ & Road J (1994). Tumor necrosis factor alpha decreases in vivo diaphragm contractility in dogs. Am J Respir Crit Care Med 150, 1368-1373.
65. Williams DL Jr & Swenson CA (1982). Disulfide bridges in tropomyosin. Effect on ATPase activity of actomyosin. Eur J Biochem 127, 495-499.
66. 2-linked cascade. J Biol Chem 275, 32357-32362.
67. Yamada T, Place N, Kosterina N, Ostberg T, Zhang SJ, Grundtman C, Erlandsson-Harris H, Lundberg IE, Glenmark B, Bruton JD & Westerblad H (2009). Impaired myofibrillar function in the soleus muscle of mice with collagen-induced arthritis. Arthritis Rheum 60, 3280-3289.
68. Yende S, Waterer GW, Tolley EA, Newman AB, Bauer DC, Taaffe DR, Jensen R, Crapo R, Rubin S, Nevitt M, Simonsick EM, Satterfield S, Harris T & Kritchevsky SB (2006). Inflammatory markers are associated with ventilatory limitation and muscle dysfunction in obstructive lung disease in well functioning elderly adults. Thorax 61, 10-16.
69. Zhan M, Jin B, Chen SE, Reecy JM & Li YP (2007). TACE release of TNF-α mediates mechanotransduction-induced activation of p38 MAPK and myogenesis. J Cell Sci 120, 692-701.
70. Zuo L, Christofi FL, Wright VP, Bao S & Clanton TL (2004). Lipoxygenase-dependent superoxide release in skeletal muscle. J Appl Physiol 97, 661-668.